(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 March 2004 (11.03.2004)

PCT

(10) International Publication Number WO 2004/020581 A2

(51) International Patent Classification7:

C12N

(21) International Application Number:

PCT/US2003/026073

- (22) International Filing Date: 15 August 2003 (15.08.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/404,311

15 August 2002 (15.08.2002) U

- (71) Applicant (for all designated States except US): FUNC-TIONAL GENETICS, INC. [US/US]; 12111 Parklawn Drive, Suite 202, Rockville, MD 20852 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LI, Limin [US/US]; 5801 Nicholson Lane, Suite 1608, North Bethesda, MD 20852 (US). AGHDASI, Bahman [IR/US]; 909 Glaizewood Avenue, Takoma Park, MD 20912 (US).

- (74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: MAMMALIAN GENES INVOLVED IN RAPAMYCIN RESISTANCE AND TUMORGENESIS: RAPR7 GENES

SEQ ID NO:1

TCNNATTCCCGAGAATAAATTTCTGTGACTAACTCTTCCTTTTGTTGGTTCTTCATGGCATATGCCTTATGAAGG TAACATACCCAAGCTGCCTCTGCCTCCCGCAGTGAACCCCTACCCTGCCCTTTGGCAGGTTCTCTTACTGACCAT CCCCACCTGCCCCACACATCCTCCCCTATGCACCCCAACTNTGAGCCCCTCCTGCTCAGTAAGTCTGTAGACTTG TACTCAGCACACANTAGGTGGATAAATACCCCCACAGTAGGTGGGTAGTGAGCCCTGTGAGTCCACTGTAAGNCA CCATCTACATGGGCANAGCCTGCTTTAAGCGTGGGTTAGGGACACCACCAGTCTTCTAGCAGGGCTTCTGGCACCATCTACACAAGTCCATCCTCAGGCTCTTCCACTCCCGGGTTCCCTCTGGACCTGTGTGACTCTGAGGAACTTGGG GAATTCCTAACCTCCCCTTTCAACTGAGCCCTTGGCTCTTGGAGTTAGCCACAACCTAACTACTCAGGTCCCTCC AACAAGGGGACTGTGTCTGTGGCTGGATGACTCATGCACACTGCTCCATCCCGCAATCTTGGGCGGGACTTGGGC TGGGGAGGATGCCAGCCAGCTCAGGCTAGGAGCTTGCATCCTGTTGCCCCAACCCAGCCCTACCAGAAAAAAAGAGTG TACTCAGAGCTCCAGGACAAAATCTGGAAACAGAGAGCCGGCTCTCATTTGGACCGAGATCTGAGTGATGAAAA GAGCAGGCAGAGGAAACAGCAAGTTCAAAGTTCCTOAGGTGGGAATGCGCTTGACACACGGAGACCTGAGAAG ACACAGCAAAGGCCGTGTTACATTTGTCTGNGACTCCAGCCCCCAAGGATCTGGTCAGGACAGACATNGCGAGGA TCTTTTTTTGNNNNNGGCCCCAAGACAGGCTTTCTTTGNGTAGCCCCGGCTGTTTTGGAACTNACTNTGTAGACC AAACTGGCCTGNGAACTCACAGAGATCCTCCTGNCTTTGNCTNCCGAGTACAAGGGTTAAAAGCCTGAGCCANTA CCACTGGCCAGGCTAACTAAGGTTCTTAACTTTTTAAGNATTATTTTTCTTATGTATGTGTATATGGGGGA GGGGATGCACAAGGGCATGGGGGGGGGTCCCTGCAGAAGTCAGAAGAGGGTGCCAGATCCCTGGGAGCTGGAATT AAAGTCAGTCATGAAACATCCAAGATGGACACTGGGNAACTGAACTTGGGTCCTCTGCGAGAGGGAGTAATGGTCT TAACTGCTGAGCCATCTCTAGGCCCAATGTCTGGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGT GCCCTGGCTGTCCTGGAACTCACTCTATAGACTAGGCTGGCCTCGAACTCAGAAATCCTCCTGCCTCTGCCTCCC AAGTGCTGAGATTAAAGGCCCGTGCCACCACTGCCCGACGCCAATGTCTGTATTTTATTCATCTCTGCAGAATCT CITITGTCTCCTAACGGAACATCATCCCAGATTCTGGGAAGTACACTGAAGACAATGGGGTGGTGTTGTTTCTC TCCTATGCCCTTTACATNCTCCCTACCTATTTCAGATGTAACCATGATCTACCAGCTCATCACAGGCCACAGCTT AAACCTCCCTC

(57) Abstract: The invention provides nucleotide sequence of a novel mammalian gene which is involved in rapamycin resistance and tumorgenesis, the RapR7 gene, and amino acid sequences of its encoded proteins, and fragments and derivatives and analogs thereof. The present invention also provides methods and compositions for regulating rapamycin resistance and/or tumorgenesis by modulating the expression and/or the activity of RapR7 gene. The invention also provides methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression and/or activity of RapR7 gene. The invention also provides methods and compositions for diagnosing and screening RapR7 mediated rapamycin resistance and/or tumorgenesis in patients. The invention further provides host cells whose RapR7 gene can be reversibly overexpressed, and to methods of using the RapR7 gene in evaluation and screening for drugs which regulate rapamycin resistance and/or tumorgenesis.

O 2004/020581 A2 ||||||